Current Partnering publishes "Anthrax Partnering 2009-2014" report

The recently published "Anthrax Partnering 2009-2014" report from Current Partnering provides understanding and access to anthrax partnering deals and agreements entered into by the world's leading healthcare companies.

The report, which provides an analysis of anthrax partnering deals, revealed that the majority of deals are discovery or development stage whereby the licensee obtains a right or an option right to license the licensor's anthrax technology. Such deals are usually multicomponent and start with collaborative research and development and commercialization of outcomes.

According to the report, an understanding of the flexibility of a prospective partner's negotiated deals terms provides critical insight into the negotiation process by fostering an idea of what can be achieved during the negotiation of terms. Many smaller companies seek details of payments clauses, but the the terms of how payments are triggered are the important details.

The report contains more than 70 links to online copies of actual anthrax deals and contract documents submitted to the Securities Exchange Commission by companies and their partners when available.

The report's first chapter provides an introduction to the report while chapter two gives an overview of the trends in anthrax partnering since 2009, including a summary of deals by industry sector, stage of development, deal type and technology type. An overview of the leading anthrax deals since 2009 is provided in chapter three while chapter four provides a comprehensive director of anthrax partnering deals signed and announced since 2009.